Proper wound diagnosis and management is an increasingly important clinical challenge and is a large and growing unmet need. Pressure ulcers, hard-to-heal wounds, and problematic surgical incisions are emerging at increasing frequencies. At present, the wound-healing industry is experiencing a paradigm shift towards innovative treatments that exploit nanotechnology, biomaterials, and biologics. Our study utilized an alginate hydrogel patch to deliver stromal cell-derived factor-1 (SDF-1), a naturally occurring chemokine that is rapidly overexpressed in response to tissue injury, to assess the potential effects SDF-1 therapy on wound closure rates and scar formation. Alginate patches were loaded with either purified recombinant human SDF-1 protein or plasmid expressing SDF-1 and the kinetics of SDF-1 release were measured both in vitro and in vivo in mice. Our studies demonstrate that although SDF-1 plasmid-and protein-loaded patches were able to release therapeutic product over hours to days, SDF-1 protein was released faster (in vivo K d 0.55 days) than SDF-1 plasmid (in vivo K d 3.67 days). We hypothesized that chronic SDF-1 delivery would be more effective in accelerating the rate of dermal wound closure in Yorkshire pigs with acute surgical wounds, a model that closely mimics human wound healing. Wounds treated with SDF-1 protein (n = 10) and plasmid (n = 6) loaded patches healed faster than sham (n = 4) or control (n = 4). At day 9, SDF-1-treated wounds significantly accelerated wound closure (55.0 ± 14.3% healed) compared to nontreated controls (8.2 ± 6.0%, p < 0.05). Furthermore, 38% of SDF-1-treated wounds were fully healed at day 9 (vs. none in controls) with very little evidence of scarring. These data suggest that patch-mediated SDF-1 delivery may ultimately provide a novel therapy for accelerating healing and reducing scarring in clinical wounds.
INTRODUCTION
the principal cells involved in stimulating blood vessel growth. In response to injury, these cells initiate the angiogenic process, which eventually leads to remodeled Wound healing is a complex and coordinated series of events involving inflammation, tissue deposition, re-tissue and a newly formed vasculature. There are many therapies directed at accelerating wound healing, such modeling, and scarring. In the epidermis, this is a dynamic process involving multiple skin layers, specifi-as the application of electric currents, living skin equivalents, and pharmacological manipulation of factors that cally the interaction of infiltrative cells (leukocytes, progenitor cells) with the underlying stroma (keratino-modulate the wound-healing process. However, few treatments are able to combine the ability to improve cytes, endothelial cells, epithelia, extracellular matrix) (26) . Angiogenesis is one of the important events during wound healing with ease of transport and efficacy in a cost-effective manner. Furthermore, there are limited wound healing, and microvascular endothelial cells are 400 RABBANY ET AL. studies that directly compare gene-and protein-based bi-hypothesized that slow-release delivery of either SDF-1 protein or plasmid expressing SDF-1 would increase the ological delivery in order to define optimal delivery strategies.
rate of wound closure in a porcine model of full-thickness dermal wound healing. We employed a clinically Dermal Delivery of Biologic Material relevant delivery system, an alginate scaffold, to deliver SDF-1 plasmid or protein over time to acute surgical Alginate hydrogels have proven to be useful scaffolds for tissue engineering and delivery vehicles for drug wounds. In this article, we characterized SDF-1 plasmid or protein dermal delivery using alginate scaffolds in treatments. Hydrogels can be loaded with a variety of growth factors for controlled release during different vitro and demonstrate the potential for therapeutic benefit in vivo by using the scaffolds to deliver the SDF-1 wound-healing stages and in light of wound severity. Furthermore, alginate gels and patches are extremely protein and plasmid to acute surgical wounds. versatile and can be tailored to account for the stiffness, MATERIALS AND METHODS swelling, cell attachment, or degradation of bioreactive Construction of Honeycomb Alginate Patches polymers (3). Improving the rate of dermal wound healing has been identified as a target for demonstrating the Chemicals were obtained from Nacalai Tesque. Inc. therapeutic potential of growth factor delivery. A num-(Kyoto, Japan), Calbiochem (La Jolla, CA, USA), BD ber of factors have been identified that mediate wound Biosciences (Franklin Lakes, NJ, USA), and Sigma healing and promote proliferation and differentiation of Chemical Co. (St. Louis, MO, USA) and used without skin cells, such as platelet-derived growth factor further purification. Alginate gels were prepared accord-(PDGF) and epidermal growth factor (EGF) (20). Our ing to the method described previously (8) . Briefly, sostudy focused on stromal cell-derived factor-1 (SDF-1), dium alginate (MW, 110k, Wako Pure Chemical Industry, a naturally occurring chemokine that is rapidly overex-Osaka, Japan) was dissolved at different concentrations in pressed in response to tissue injury, particularly during distilled water. The inner wall of glass beakers was ischemia, to expedite wound closure and decrease scar coated with a thin layer of sodium alginate and dried at formation (2,15). SDF-1 plays an important role in the 110°C for 0.5 h. An aqueous solution of sodium alginate migration, recruitment, and retention of endothelial prowas poured into the alginate-coated beaker and calcium genitor cells (EPCs) to the site of injury, hence contribchloride solution was sprayed until a thin alginate gel uting to neovascularization. Findings from multiple inlayer was formed on the top of the sodium alginate soludependent studies suggest that inducing SDF-1 expression tion. Then, calcium chloride solution was added on the at a wound site has therapeutic potential to promote thin gel layer, followed by overnight incubation at room rapid repair of hard-to-heal wounds, such as deep incitemperature to complete gelation. This ionotropic gelasions, ulcerations, and burns (5,6,10). tion generated parallel channel-like pores in alginate gels, which were subsequently washed with deionized Therapeutic Applications of SDF-1 water to remove free calcium ions. The resulting gels A unique aspect of wound healing in adult tissue is were frozen at −80°C, lyophilized under vacuum at that regeneration is generally driven by environmental room temperature for 2 days to form a honeycomb strucstimuli and is often initiated by local release of chemoture, cut into 5 mm diameter/2 mm thick disc-shaped kines. SDF-1 treatment has been shown to reduce wound units, and subjected to further chemical modifications. size by recruiting progenitor cells to the site of injury, Alginate discs were immersed in 2-(N-morpholino) promoting full reepithelialization of the wound and enethanesulfonic acid (MES) buffer (0.2 M, pH 6.0) conhancing revascularization of the damaged tissue. A taining ethylenediamine (ED, 5.17 mM), NHS (114 prominent feature of this treatment is the decreased amount mM), and 1-ethyl-3-(3-dimethylaminopropyl) carbodiiof tissue scarring, a particularly important feature that mide (EDC, 305 mM) and centrifuged at 1500 rpm for will increase the health, mobility, and well-being of pa-5 min to eliminate air bubbles. After 24 h of cross-linktients. The beneficial effects of SDF-1 treatment are well ing, the resulting gels were washed with phosphatecharacterized in cardiovascular models of ischemia and buffered saline (PBS) three times. hypoxic stress (7, 30) . Similarly, dermal wounds may be Radioiodination of SDF-1 Protein a particularly relevant therapeutic target for SDF-1 therapy due to the ability of SDF-1 to recruit EPCs and Human recombinant SDF-1 was radioiodinated according to the method of Greenwood et al. (12) . Briefly, epithelial cells and thus accelerate natural wound repair. Importantly, SDF-1 treatment has been shown to accel-10 µl of Na 125 I solution was added to 40 µl of 0.1 mg/ ml SDF-1 solution, followed by the addition of 0.2 mg/ erate wound healing. In two studies, direct injection of SDF-1 protein or lentivirus significantly reduced wound ml of chloramine-T potassium phosphate-buffered solution (0.5 M, pH 7.5) containing 0.5 M sodium chloride size after 1 week in diabetic mice (5,11). We therefore (100 µl). After agitation at room temperature for 2 min, into the backs of 6-week-old female ddY mice (Shimizu Laboratory Supply Inc., Japan) at the central position 15 100 µl of PBS solution (pH 7.5) containing 0.4 mg of sodium metabisulfate was added to the reaction solution mm away from their tail root. At different time intervals, the mouse skin including the implanted site of the to stop the radioiodination. The reaction mixture was passed through an anionic-exchange column to remove sponge (3 × 5 cm) was excised and the corresponding fascia was thoroughly wiped off with a filter paper to the uncoupled, free 125 I molecules from the 125 I-labeled SDF-1 protein.
absorb 125 I-labeled SDF-1 protein or plasmid DNA. The radioactivity of the patch, the excised skin strip, and the Radioiodination of SDF-1 Plasmid DNA filter paper were measured on a gamma counter (ARC-380) to assess the time profile of in vivo SDF-1 protein PBS containing 1.5 mg/ml of SDF-1 plasmid DNA (1.33 ml) was added to the 125 I-Bolton-Hunter reagent and plasmid DNA release. The experimental group was composed of three mice unless otherwise mentioned. nitrogen dried. The resulting solution was kept at room temperature for 6 h to introduce 125 I residue into the The use of animals in this study was approved by MPI's Research Institutional Animal Care and Use Committee amino groups of SDF-1 plasmid DNA. Noncoupled, free 125 I-labeled reagent was separated from 125 I-labeled SDF-(IACUC) prior to starting, and was based on current International Conference on Harmonisation (ICH) Tripar-1 plasmid DNA by gel filtration with a PD-10 column (Amersham Pharmacia Biotech K.K, Tokyo, Japan).
tite Guidelines.
Porcine Surgical Wound Healing Model Preparation of Alginate Patches Incorporating

I-Labeled SDF-1 Protein or I-Labeled and Antemortem Follow-up SDF-1 Plasmid DNA
A standard model of acute surgical wound healing was performed in domestic Yorkshire pigs. A cuffed en-Cross-linked alginate patches were immersed into 0.015 M spermine chloride/MES buffer solution con-dotracheal tube was placed and general anesthesia was maintained with isoflurane delivered in oxygen through taining NHS (114 mM) and EDC (305 mM), and stored at room temperature overnight. Unbound spermine chlo-a rebreathing system with ventilator assist. Each animal received 12 full-thickness 5-cm incisions (six on each ride was removed by washing with PBS and distilled water. After lyophilization, the spermine-immobilized side of the spine) spaced approximately 7.5 cm apart. Each incision was made perpendicular to the spine, start-patch was sterilized with 70% ethanol and air dried in an aseptic tissue culture hood. An aqueous solution (20 ing 7.5 cm from the spine and cutting toward the abdomen. Gauze was placed in the incision until the bleeding µl) of 125 I-labeled SDF-1 protein (1.0 ng/µl) containing sodium heparin (1 U/µl) was dropped onto the sterilized stopped. The gauze was removed, and the incision was sutured closed. scaffolds and incubated at 4°C overnight to complete protein incorporation. Similarly, 15 µl of an aqueous so-Alginate patches (1 × 6 cm) incorporating SDF-1 protein, plasmid DNA, or PBS were applied to wounds. lution of 125 I-labeled SDF-1 plasmid (1.0 mg/ml) was dropped onto the sterilized scaffolds and incubated at Scaffolds were prepared with a solution of plasmid encoding human SDF-1 in a pcDNA3.1 backbone (In-4°C overnight to complete plasmid DNA incorporation.
vitrogen Corporation, Carlsbad, CA, USA) by mixing In Vitro Evaluation of SDF-1 Protein and Plasmid 3.5 mg of the SDF-1 plasmid in 2.33 ml PBS to create DNA Release From Alginate Patches a 1.5 mg/ml solution. For the SDF-1 protein scaffolds, a solution was prepared by mixing 10 µg of carrier-free An alginate patch saturated with 125 I-labeled SDF-1 protein or plasmid DNA was placed in 1 ml of PBS SDF-1 protein (R&D Systems, Minneapolis, MN, USA) with 5 ml PBS and 3 ml of 1000 IU/ml injection heparin containing bovine serum albumin fraction V (BSA, 0.1 mg/ml), followed by incubating at 37°C. The superna-(Baxter Healthcare Corporation, Deerfield, IL, USA) to create a 1.5 µg/ml solution. PBS scaffolds served as a tant was periodically sampled to measure the radioactivity of released 125 I-labeled SDF-1 protein or plasmid negative control and were prepared by mixing 1.35 ml PBS and 0.45 ml of 1000 IU/ml injection heparin. On DNA by a gamma counter (ARC-380, Aloka Co., Ltd., Japan). Fresh BSA solution of the same volume was each scaffold, the loading solution was pipetted under sterile conditions onto the scaffold in six equally spaced added to continue the release test.
60-µl drops (360 µl total) so that each drop covered a In Vivo Evaluation of SDF-1 Protein and SDF-1 1-cm 2 area of the scaffold. All loaded scaffolds were Plasmid DNA Release From Alginate Patches stored at 4°C for 12 h prior to wound application. in Rodents
Following wound closure, the scaffold was placed next to the wound and photographed. The scaffold Alginate patches incorporating 125 I-labeled SDF-1 protein or plasmid DNA were implanted subcutaneously placement order was randomized with the following dis-tribution: SDF-1 protein (n = 10), SDF-1 plasmid (n = formed using Microsoft Office Excel 2007 (Microsoft, Redmond, WA, USA). 6), PBS (n = 4), or sham (no scaffold, n = 4) wounds. The scaffold was placed over the wound (except in the RESULTS sham group), and each wound was dressed with a Tegaderm patch. To determine the effect of SDF-1 on the SDF-1 Protein and Plasmid Release Characteristics rate of wound healing, wound length was measured by Release characteristics of radioiodinated SDF-1 prothe same veterinarian at day 0 (prior to scaffold placetein and plasmid from alginate scaffolds are shown in ment) and prior to sacrifice. Wound length was con- Figure 1 . SDF-1 protein and plasmid release in vitro was verted to percent healing by the following equation: (inimeasured at multiple time points over 150 h (Fig. 1A) . tial wound length − final wound length)/(initial wound
The scaffolds released approximately 40-60% of plaslength) × 100%. To monitor the time course of the efmid or protein SDF-1 within the first day, with K d of fects of SDF-1 on wound healing, the first pig was sacri-24.5 and 15.8 h, respectively. Thereafter, SDF-1 plasmid ficed at 4 days and the second pig was sacrificed at 9
continued to be released, whereas SDF-1 protein release days.
was minimal after 24 h. Because neither the SDF-1 plas-
Postmortem Follow-up
Following sacrifice, one section from the middle of each wound site was excised for histopathological and immunohistochemical analysis. Standard hematoxylin and eosin (H&E) stain was used to assess extent of fibroplasia, inflammation, and necrosis at day 4 and necrosis, fibrosis, and granulomatous inflammation at day 9. Each parameter was graded on a qualitative scale by a histopathologist blinded to randomization as either: none (not present), minimal, mild, moderate, or severe. Immunohistochemical staining was performed on the same tissue section.
The effect of SDF-1 on fibroblast infiltration into the wound was detected by vimentin staining. Vimentin is a type III intermediate filament often expressed in epithelial cells undergoing mesenchymal transition. The effect of SDF-1 on blood vessel formation was determined by CD31 and the presence of smooth muscle was detected by smooth muscle actin staining. CD31, also known as platelet endothelial cell adhesion molecule 1 (PECAM1), is a type I integral membrane glycoprotein and a member of the immunoglobulin superfamily of cell surface receptors. It is constitutively expressed on the surface of endothelial cells and concentrated at the junction between them. CD31 has been used to measure angiogenesis and can be used as a marker for myeloid progenitor cells. Smooth muscle α-actin is used because it is one of a few genes whose expression is relatively restricted to vascular smooth muscle cells. The amount of each stain per sample was graded by the same pathologist using the same qualitative scale as above. fit to each data set. All statistical analyses were per-mid nor protein reached 100% release at 1 week, we ensured the patches retained the originally loaded SDF-1 by detaching the remaining protein or plasmid from the patch by soaking in a high salt solution (data not shown), suggesting that release may have reached equilibrium with the supernatant. This indicated that subcutaneous scaffold application in vivo may sustain plasmid and protein release over time, and may be effective release of therapeutic vectors or proteins.
To test this hypothesis in vivo, SDF-1 plasmid and protein scaffolds were implanted subcutaneously into the backs of 6-week-old ddY female mice and evaluated for release over 2 weeks (Fig. 1B) . The in vivo profile of SDF-1 protein release was similar to the in vitro profile, as the majority of the SDF-1 protein was released within the first day (K d , 0.55 days) compared to the in vivo release of SDF-1 plasmid, which demonstrated a slower release profile (K d 3.67 days). Dissociation values are presented in Table 1 . The total amount of SDF-1 plasmid released initially was significantly lower than that of protein for the first 6 days, while the amount remaining after 2 weeks was similar. Based on these release characteristics, we tested the effects of SDF-1 treatment in a well-characterized porcine model of dermal wound healing. We hypothesized that SDF-1 treatment would increase treated groups (n = 8) healed to a much greater extent comthe rate of healing in acute dermal wounds, such as those pared to nontreated controls (n = 4). *p < 0.05. received after surgery. Therefore, 5-cm-long full-thickness incisions were made on the backs of Yorkshire pigs ment significantly accelerated wound closure (55.05 ± and covered with Tegaderm alone or scaffolds soaked 14.36%) compared to controls (8.14 ± 5.96%, p < 0.05). with PBS, SDF-1 plasmid, or SDF-1 protein to assess Representative examples of wounds treated with PBS the effect of SDF-1 treatment on the rate of dermal (Fig. 3A, D, G) , SDF-1 protein (Fig. 3B, E, H) , or SDFwound closure.
SDF-1-Releasing Scaffold Accelerates Wound Healing
1 plasmid (Fig. 3C , F, I) scaffolds at day 0 (top panel) The impact of SDF-1-releasing scaffolds on wound and day 9 (bottom panel) are shown. At day 9, the healing is shown in Figure 2 . Wounds treated with either wound treated with the control scaffold was still appar-SDF-1 plasmid or protein scaffolds ( Fig. 2A, solid ent, whereas there was no visible evidence of the SDF-1 markers and lines) trended towards accelerated wound protein-and SDF-1 plasmid-treated wounds (Fig. 3G-I) . healing by day 4 and demonstrated a significantly higher Notably, one of three SDF-1 plasmid-treated wounds rate of wound closure compared to control wounds at and two of five SDF-1 protein-treated wounds are 100% day 9 post-scaffold application ( Fig. 2A, dotted lines) .
healed at 9 days (Fig. 3J ). Grouped data (Fig. 2B ) demonstrate that SDF-1 treat-SDF-1 has previously been shown to cause neovascularization (21, 30) and promote homing of progenitor cells (11, 28) . It is recently appreciated that SDF-1 may on fibroblast infiltration, smooth muscle, and new blood but no difference was observed in subacute/chronic inflammation or necrosis between groups (Fig. 5B-D) . vessel formation, using immunohistochemical staining for vimentin ( Fig. 4A-H) , smooth muscle actin (Fig.  DISCUSSION  4I-L) , and PECAM-1 (CD31) (Fig. 4K-O) , respectively. A slight increase in vimentin staining was ob-Wound dressings capable of delivering proangiogenic factors play a vital role in the early healing process, by served in PBS-treated compared to SDF-1-treated wounds, which may reflect differences observed in scar leaving wounds from being undisturbed and keeping wounds intact at body temperature, giving the body a formation. There were no substantial differences in the amount of CD31 or smooth muscle actin staining com-chance to heal by recruiting the much needed blood supply. In this study, we demonstrated that a novel wound pared between treatment groups. H&E analysis showed a slight decrease in fibrosis in the SDF-1 protein-and dressing, an alginate scaffold releasing the proangiogenic molecule SDF-1, accelerated the wound-healing plasmid-treated wounds compared to control or sham wounds (Fig. 5A) . Similarly, a slight increase in granu-process in a clinically relevant animal model of acute surgical wound healing. Furthermore, we characterized lotamous inflammation was observed in control groups, SDF-1 release kinetics from the scaffold for both the cans and growth factor binding proteins, which protect the growth factors from enzymatic digestion and regu-SDF-1 plasmid and the SDF-1 protein. Interestingly, the time course of the in vivo release kinetics differed be-late certain in vivo biological activities. In regenerating tissues and organs, the binding of extracellular matrix tween plasmid and protein; however, the SDF-1-induced wound-healing benefit was observed independent of the proteins and proteoglycans to growth factors is mitigated by enzymes secreted by the healing tissue, leading to the delivery modality.
Several investigators have employed model proteins release of growth factors in a biologically active form. It has been previously reported that the stability or resis-such as albumin and IgG to examine protein release from carriers. Some used recombinant proteins, but very tance of growth factor proteins and plasmids against proteinases or DNases is increased in biodegradable gel-few have shown in vivo release profiles. As shown in Figures 1 and 2 , we found that the difference between atin hydrogels due to their binding with gelatin molecules (14, 24) . Based on this mechanism, we mimicked the in vivo and in vitro profiles for both the SDF-1 protein and plasmid may be due to the displacement of the the naturally occurring release system for growth factor proteins or plasmids and extended their biological activ-SDF-1 protein with other heparin-binding proteins or to the biological responses to the implanted vehicles. We ity in vivo by controlling their release from gelatin hydrogels. did not check the stability of SDF-1 protein and plasmid, but rather the remaining radioactivity of radiolabeled As shown in Figure 2 , we found that the alginate patches prolonged the in vivo retention of both SDF-1 SDF-1 protein and plasmid.
Protein and plasmid can be cleaved by proteinases protein and plasmid over 2 weeks. Because heparin and spermine introduced into the presented alginate scaf-and DNases in the body, respectively. Thus, some mechanisms that allow SDF-1 protein and plasmid to exhibit folds can bind to SDF-1 protein and plasmid, respectively, this result strongly suggests that SDF-1 protein their bioactivities by protecting them from enzymatic digestion should be considered to explain the accelerated and plasmid binds to patches and consequently achieves the prolonged in vivo retention in a biologically active wound healing observed after therapeutic application of SDF-1 protein and plasmid. It is well known that many form.
As described above, the release of the plasmid was growth factors are stored in the body by binding to extracellular matrices, such as heparin sulfate proteogly-markedly slower compared to the protein in vivo (Fig.  1 ). However, both provided similar acceleration of the tal development heal without remnants of a scar (16, 17) . One of the important molecular pathways responsible healing of surgical wounds (Figs. 2 and 3 ). There are a number of potential explanations. SDF-1's wound-heal-for regulating fetal development in a number of organ systems is the sonic hedgehog-Gli pathway (9) , which ing benefit may be relatively time independent, and delivery of SDF-1 within a certain number of days follow-has been implicated in healing ischemic injury as well. Delivery of a sonic hedgehog (Shh) plasmid to cardiac ing wound creation is sufficient. In contrast to the kinetics of SDF-1 protein, which releases quickly in ischemic tissue has improved cardiac function (9, 13) . In both this myocardial injury model and in wound-healing vivo, only 20% of SDF-1 plasmid is released 1 day following delivery and is likely not significantly expressed models, treatment with Shh has been shown to upregulate SDF-1 and SDF-1's enhancement of EPC homing until at least 24 h after delivery, but 75% is released after 6 days (Fig. 1) . Although the release characteristics to the site of injury (1,13). Therefore, our data suggest that Shh-mediated SDF-1 upregulation may be the differed, both SDF-1 protein and plasmid treatment accelerated wound healing (Fig. 2) . A second explanation mechanism by which there is decreased scarring following fetal surgery. If correct, our data further suggest that might be that SDF-1 must be delivered close to the time of wound creation. However, in this study an exception-SDF-1 overexpression in adult would healing may be a strategy to decrease scar formation in adulthood. Inter-ally high dose of SDF-1 was delivered, so that even 20% of total plasmid release/60% of protein release after 1 estingly, our histology does not demonstrate a significant increase in vascular density in those animals that day is sufficient to provide benefit. This is supported by previous work demonstrating that the application of received SDF-1 protein or plasmid. This lack of angiogenesis suggests that the benefits associated with SDF-SDF-1 within 2 days postwounding is effective in accelerating the healing of diabetic wounds (11) . Further-1 treatment in our study may be a mechanism other than EPC homing. more, under different experimental conditions, stem cell homing has been induced with lower concentrations of In conclusion, continuous delivery of the proangiogenic modulator, SDF-1 plasmid or protein, through an SDF-1 protein and plasmid than those used in this study (22, 25) .
alginate scaffold significantly accelerates wound healing and may reduce scarring in a clinically relevant acute Histological analysis of the wound measured by PECAM-1 (CD31) on day 9 revealed that the SDF-1 surgical wound model. release decreased vascularization of the wound. Simi-
